Fisher Vicki L, Barnes Yvonne J, Nuss Suzanne L
Pediatric Blood and Marrow Transplant Program, University Hospitals of Cleveland, USA.
Oncol Nurs Forum. 2006 Nov 3;33(2):E36-43. doi: 10.1188/06.ONF.E36-E43.
PURPOSE/OBJECTIVES: To provide clinical insights into dosing and administration of IV busulfan, a conditioning agent for hematopoietic stem cell transplantation (HSCT).
Review of published literature related to busulfan pretransplant conditioning using MEDLINE. Meeting abstracts, investigational protocols, and pharmaceutical manufacturers' package inserts also were reviewed.
Busulfan is an effective myeloablative conditioning agent for HSCT. The IV formulation increases dose assurance and the ability to target a therapeutic window. Therapeutic drug monitoring ensures that targeted blood levels are achieved, especially in children, thereby preventing underdosing, which can lead to disease progression or rejection, as well as overdosing, which can cause an increased risk of toxic side effects.
IV busulfan is a convenient, safe, and effective conditioning agent used in HSCT that has a predictable pharmacokinetic profile.
An understanding of the pharmacokinetic principles underlying the relationship between the therapeutic window for busulfan and optimal HSCT outcomes will facilitate proper dosing and administration of IV busulfan.
目的/目标：为造血干细胞移植（HSCT）预处理药物静脉注射白消安的给药方法提供临床见解。
使用MEDLINE对已发表的与白消安移植前预处理相关的文献进行综述。会议摘要、研究方案以及制药商的药品说明书也在综述范围内。
白消安是一种用于HSCT的有效的清髓性预处理药物。静脉注射剂型提高了剂量的准确性以及达到治疗窗浓度的能力。治疗药物监测可确保达到目标血药浓度，尤其是在儿童中，从而避免导致疾病进展或移植排斥的剂量不足以及会增加毒副作用风险的剂量过量。
静脉注射白消安是一种用于HSCT的方便、安全且有效的预处理药物，其药代动力学特征可预测。
了解白消安治疗窗与最佳HSCT结果之间关系的药代动力学原理，将有助于正确给予静脉注射白消安。
